Literature DB >> 11312386

Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival.

A J MacGregor1, R Canavan, C Knight, C P Denton, J Davar, J Coghlan, C M Black.   

Abstract

OBJECTIVE: To assess the rate of progression of pulmonary hypertension (PHT) in systemic sclerosis (SSc) and its bearing on mortality.
METHODS: A retrospective record review of 930 patients with SSc attending a specialist centre was carried out. Those at risk for both idiopathic and secondary PHT were assessed by serial Doppler echocardiography. Mortality data were reviewed.
RESULTS: The cumulative prevalence of PHT was 13%. Pressures remained static in most cases. The mortality among those with a single pressure reading of 30 mmHg or higher was 20% at 20 months. An increased mortality risk was associated with high initial pressures and rising pressures. Rapid pressure rises occurred more frequently in limited than in diffuse SSC.
CONCLUSIONS: The prevalence of PHT in SSc is high and the detection of PHT at any time in the disease course is associated with substantial mortality. These results demonstrate the value of echocardiographic screening for PHT in all patients with SSC.

Entities:  

Mesh:

Year:  2001        PMID: 11312386     DOI: 10.1093/rheumatology/40.4.453

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  39 in total

1.  Predictors of end stage lung disease in systemic sclerosis.

Authors:  V Steen
Journal:  Ann Rheum Dis       Date:  2003-02       Impact factor: 19.103

Review 2.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

3.  Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.

Authors:  Rajeev Saggar; Dinesh Khanna; Daniel E Furst; Shelley Shapiro; Paul Maranian; John A Belperio; Neeraj Chauhan; Philip Clements; Alan Gorn; S Sam Weigt; David Ross; Joseph P Lynch; Rajan Saggar
Journal:  Arthritis Rheum       Date:  2010-12

4.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Authors:  C P Denton; M Humbert; L Rubin; C M Black
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

5.  The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.

Authors:  Hyo Jin Choi; Young Kee Shin; Hyun Joo Lee; Joo Young Kee; Dong Woo Shin; Eun Young Lee; Yun Jong Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Clin Rheumatol       Date:  2007-09-25       Impact factor: 2.980

6.  Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry.

Authors:  Francisco J García-Hernández; María J Castillo-Palma; Carles Tolosa-Vilella; Alfredo Guillén-Del Castillo; Manuel Rubio-Rivas; Mayka Freire; José A Vargas-Hitos; José A Todolí-Parra; Mónica Rodríguez-Carballeira; Gerard Espinosa-Garriga; Dolores Colunga-Argüelles; Norberto Ortego-Centeno; Luis Trapiella-Martínez; María M Rodero-Roldán; Xavier Pla-Salas; Isabel Perales-Fraile; Isaac Pons-Martín Del Campo; Antonio J Chamorro; Rafael A Fernández-de la Puebla Giménez; Ana B Madroñero-Vuelta; Manuel Ruíz-Muñoz; Vicent Fonollosa-Pla; Carmen P Simeón-Aznar
Journal:  Clin Rheumatol       Date:  2018-12-07       Impact factor: 2.980

Review 7.  Genetics of systemic sclerosis-associated pulmonary arterial hypertension: recent progress and current concepts.

Authors:  Sanjiv J Shah
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

Review 8.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

9.  How should we treat vascular and fibrotic lung disease in scleroderma?

Authors:  Jared N Kravitz; Charlie Strange
Journal:  F1000 Med Rep       Date:  2009-07-27

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.